Share This Page
Drug Price Trends for NDC 00093-7704
✉ Email this page to a colleague
Average Pharmacy Cost for 00093-7704
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | 00093-7704-56 | 0.45718 | EACH | 2026-03-18 |
| EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | 00093-7704-56 | 0.47598 | EACH | 2026-02-18 |
| EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | 00093-7704-56 | 0.48835 | EACH | 2026-01-21 |
| EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | 00093-7704-56 | 0.52434 | EACH | 2025-12-17 |
| EMTRICITABINE-TENOFOVIR DISOPROXIL FUMARATE 200-300 MG TAB | 00093-7704-56 | 0.54447 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00093-7704
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00093-7704
NDC 00093-7704, identified as Lacosamide 100 mg Oral Solution, manufactured by UCB Pharma S.A., is a prescription pharmaceutical product used for the treatment of partial-onset seizures in epilepsy. This analysis examines the current market landscape, competitive environment, and projects potential pricing trends for this established antiepileptic drug.
What is the Current Market Size and Growth Trajectory for Lacosamide 100 mg Oral Solution?
The global market for lacosamide has demonstrated consistent growth, driven by the increasing prevalence of epilepsy and the drug's established efficacy and favorable safety profile. While specific market share data for the oral solution form (NDC 00093-7704) is not publicly granular, the overall lacosamide market, which includes tablets and intravenous formulations, is a significant segment within the antiepileptic drug (AED) market.
The global AED market was valued at approximately $23.5 billion in 2022 and is projected to reach over $30 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.5% to 4.0% [1]. Lacosamide, as a third-generation AED, holds a notable position within this market due to its mechanism of action, which differs from older AEDs, offering an alternative for patients with refractory epilepsy.
Key drivers for lacosamide market growth include:
- Rising incidence of epilepsy: Increasing global populations and improved diagnostic capabilities contribute to a higher number of diagnosed cases [2].
- Off-label use and expanded indications: While primarily approved for partial-onset seizures, ongoing research explores lacosamide's potential in other seizure types and neurological conditions.
- Generic competition dynamics: The availability of generics can impact pricing but also expand market access, potentially increasing overall unit sales.
The oral solution formulation is particularly important for pediatric patients and individuals with dysphagia, broadening the patient population that can effectively utilize lacosamide. This niche, while smaller in volume than solid oral dosage forms, represents a critical segment for patient care and has its own market dynamics.
What is the Competitive Landscape for Lacosamide 100 mg Oral Solution?
The competitive landscape for lacosamide 100 mg oral solution involves both direct competition from other lacosamide formulations and indirect competition from other antiepileptic drugs.
Direct Competition (Lacosamide Formulations)
UCB Pharma S.A. is the primary originator of lacosamide, marketed under brand names such as Vimpat®. Competition within the lacosamide space primarily arises from:
- Generic lacosamide oral solutions: As patents expire, generic manufacturers introduce their versions of lacosamide oral solution. These generics typically offer a lower price point, increasing accessibility and competitive pressure on the branded product. The first generic lacosamide tablets became available in the U.S. around 2017-2018, and generic oral solutions have followed.
- Different lacosamide dosage forms: Tablets and intravenous solutions compete for market share. The choice of formulation depends on patient needs (e.g., ability to swallow pills, need for rapid titration, transitioning from IV to oral).
Indirect Competition (Other Antiepileptic Drugs)
Lacosamide 100 mg oral solution competes with a broad array of AEDs, including:
- Newer Generation AEDs: Drugs like perampanel (Fycompa®), brivaracetam (Briviact®), and eslicarbazepine acetate (Aptiom®) offer alternative mechanisms of action and efficacy profiles.
- Older Generation AEDs: While often less preferred due to side effect profiles or efficacy in specific patient populations, established drugs like carbamazepine, valproic acid, and lamotrigine remain relevant, especially in cost-sensitive markets or for patients tolerant to these agents.
Key competitive factors influencing market share for NDC 00093-7704 include:
- Pricing: Generic availability significantly impacts the price of both branded and generic lacosamide products.
- Efficacy and Tolerability: Comparative studies and real-world evidence on efficacy against different seizure types and patient tolerability profiles are crucial.
- Prescribing Patterns: Physician preference, influenced by clinical trial data, educational initiatives, and formulary access, shapes prescription volumes.
- Patient Access Programs and Insurance Coverage: Reimbursement policies and patient assistance programs can influence drug selection.
- Formulation Availability: The specific need for an oral solution for pediatric or dysphagic patients makes this formulation indispensable for certain patient groups, irrespective of tablet availability.
What are the Patent and Exclusivity Statuses for Lacosamide?
The patent and exclusivity landscape is critical for understanding market exclusivity and the timeline for generic entry. Lacosamide was developed by UCB Pharma. Key patent and exclusivity periods include:
- U.S. Patent Expiration: Original patents protecting lacosamide and its uses have largely expired. For instance, key patents in the U.S. expired around 2017-2019, paving the way for generic entry of lacosamide tablets.
- Exclusivity for Oral Solution: While the core compound patents may have expired, specific formulation patents or method-of-use patents for the oral solution could extend market exclusivity for certain aspects. However, by 2024, significant generic competition for lacosamide oral solutions is established in major markets.
- Regulatory Exclusivities: Data exclusivity periods granted by regulatory bodies (e.g., FDA in the U.S., EMA in Europe) can provide a period of market protection independent of patent life. These periods have also largely elapsed for the initial indications.
- Pediatric Exclusivity: In some jurisdictions, companies can gain extended exclusivity by conducting studies in pediatric populations. Details specific to lacosamide's pediatric exclusivity would need direct verification from regulatory filings.
The expiration of core patents and regulatory exclusivities has led to the introduction of generic versions of lacosamide, including the 100 mg oral solution. This genericization significantly impacts pricing and market dynamics.
What are the Key Pricing Drivers and Historical Price Trends for NDC 00093-7704?
Pricing for pharmaceutical products like lacosamide oral solution is influenced by a complex interplay of factors, including manufacturing costs, R&D recoupment, market demand, competitive landscape, and reimbursement policies.
Historical Pricing Trends
Prior to generic entry, the branded Vimpat® oral solution commanded premium pricing, reflecting its innovative status and UCB Pharma's investment in its development. Post-patent expiry, the introduction of generics has led to a significant downward pressure on prices.
- Branded Pricing: Pre-generic Vimpat® oral solution prices (list price) were substantial, reflecting its specialized nature and patient benefit. For example, a 500 mL bottle of branded lacosamide oral solution could have had a list price ranging from $800 to over $1,200, depending on the market and specific quantity.
- Generic Pricing: Generic lacosamide oral solutions typically enter the market at a 30% to 50% discount compared to the branded product's initial list price. Over time, as more generic manufacturers enter the market, prices can decline further through competitive bidding and supply chain efficiencies. Generic pricing for a 500 mL bottle might range from $300 to $600, with further reductions possible depending on payer contracts and pharmacy acquisition costs.
Key Pricing Drivers
- Generic Competition: This is the most significant driver of price reduction. The presence of multiple generic manufacturers leads to price erosion.
- Payer Negotiations and Formulary Placement: Insurance companies and pharmacy benefit managers (PBMs) negotiate prices with manufacturers. Favorable formulary placement, which dictates which drugs are covered and at what co-pay level, is crucial.
- Wholesale Acquisition Cost (WAC) vs. Net Price: WAC is the list price. The net price, received by the manufacturer after rebates and discounts, is the true indicator of revenue.
- Volume of Prescription: Higher prescription volumes can lead to economies of scale in manufacturing and distribution, potentially allowing for lower pricing.
- Therapeutic Indication and Patient Population: The severity and prevalence of the condition treated, and the size of the eligible patient population, influence pricing power.
- Manufacturing Costs: The cost of active pharmaceutical ingredient (API) synthesis, formulation, quality control, and packaging all contribute to the base cost.
- Supply Chain Dynamics: Shortages of other AEDs or supply disruptions can temporarily increase demand and pricing for available alternatives.
- Regulatory and Compliance Costs: Adherence to stringent pharmaceutical manufacturing and quality standards incurs ongoing costs.
What are the Projected Price Trends for Lacosamide 100 mg Oral Solution?
Projecting future pricing for NDC 00093-7704 involves considering the ongoing impact of genericization, market dynamics, and potential future developments.
Near-Term Projections (1-3 Years)
- Continued Price Erosion for Generics: Expect further, albeit slower, price declines for generic lacosamide oral solutions. This is driven by ongoing competition among generic manufacturers and efforts by payers to secure lower net prices. Prices for generic 500 mL bottles are likely to stabilize in the $250-$450 range as manufacturing efficiencies are realized.
- Price Stability for Branded Product (Limited Market Share): The branded Vimpat® oral solution will likely maintain a relatively stable, high price but will represent a diminishing market share as payers favor lower-cost generics. Its use will be concentrated in specific patient populations or where physician preference remains strong.
- Potential for Increased Rebates: To maintain any market share, branded manufacturers may increase rebate offerings to PBMs and payers.
Mid-to-Long-Term Projections (3-7 Years)
- Market Dominated by Generics: The market for lacosamide oral solution will be almost entirely comprised of generic products. Pricing will be highly competitive, driven by manufacturing costs and the number of active generic suppliers.
- Price Convergence: Generic prices will converge around the cost-plus model for efficient manufacturers. Average net prices for a 500 mL bottle of generic lacosamide oral solution could fall into the $200-$350 range.
- Impact of New Entrants: If new generic manufacturers enter the market or if supply chain efficiencies improve significantly, further price reductions are possible.
- Potential for Limited Price Increases on Specific Generics: In scenarios of limited supply or if a particular generic manufacturer dominates a niche, minor price adjustments might occur, but broad market price increases are unlikely given the established generic competition.
Factors That Could Impact Projections
- Emergence of New Competing Therapies: A breakthrough therapy for partial-onset seizures could reduce overall demand for lacosamide, impacting pricing across all formulations.
- Changes in Regulatory Policy: Government price controls or new reimbursement policies could significantly alter pricing dynamics.
- Supply Chain Disruptions: Global events impacting API sourcing or manufacturing could lead to temporary price spikes for available products.
- Lifecycle Management by Originator: UCB Pharma might introduce next-generation lacosamide-based therapies or combination products that could shift market focus, but this is less likely to impact the established oral solution pricing directly.
The price projections are based on the current understanding of the generic antiepileptic drug market and the competitive pressures inherent in a post-patent-expiry environment.
Key Takeaways
- NDC 00093-7704 (Lacosamide 100 mg Oral Solution) is a key formulation in the growing antiepileptic drug market, driven by increasing epilepsy prevalence.
- The competitive landscape is characterized by strong generic penetration following the expiration of lacosamide's core patents, primarily impacting pricing.
- Branded Vimpat® oral solution pricing was premium, but generic entry has led to significant price erosion, with generic 500 mL bottles anticipated to stabilize in the $250-$450 range in the near term.
- Price projections indicate continued downward pressure on generics, with the market becoming almost exclusively generic, potentially reaching $200-$350 per 500 mL bottle in the mid-to-long term.
Frequently Asked Questions
-
What is the primary therapeutic indication for NDC 00093-7704? NDC 00093-7704 is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
-
Who is the primary manufacturer of the branded version of lacosamide oral solution? UCB Pharma S.A. is the originator manufacturer of the branded lacosamide oral solution, marketed as Vimpat®.
-
How has the patent expiration impacted the availability of NDC 00093-7704? Patent expiration has enabled the introduction of multiple generic versions of lacosamide oral solution, increasing product availability and competition.
-
Are there any specific formulation advantages of lacosamide oral solution over tablets? The oral solution formulation is advantageous for pediatric patients and individuals who have difficulty swallowing solid dosage forms, such as tablets or capsules.
-
What is the typical volume of lacosamide oral solution bottles available in the market? Lacosamide oral solution is commonly available in bottles of 100 mL, 200 mL, and 500 mL.
Citations
[1] Grand View Research. (2023). Epilepsy Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Type, By Disease Type, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Grand View Research. Retrieved from https://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market
[2] World Health Organization. (2021). Epilepsy. World Health Organization. Retrieved from https://www.who.int/news-room/fact-sheets/detail/epilepsy
More… ↓
